Upcoming webinar: CNS Target Engagement & Proof-of-Mechanism

Demonstrating target engagement and proof-of-mechanism remains one of the key challenges in CNS drug development. Understanding whether a therapeutic reaches the central nervous system, engages its intended target and produces meaningful biological effects is essential for informed development decisions.

To explore how these challenges can be addressed in practice, CHDR and Ardena will host a joint webinar on 19 October 2026. During the session, experts from both organisations will discuss how integrated clinical pharmacology and bioanalytical strategies can be used to demonstrate target engagement and establish proof-of-mechanism in humans.

What will be covered?

The webinar will explore:

• Approaches to demonstrating CNS target engagement in clinical studies

• How biomarkers can support proof-of-mechanism

• Key considerations when designing a biomarker strategy

• The role of fit-for-purpose bioanalytical methods in early development

• How integrated clinical and bioanalytical data can support faster, data-driven decision making

Using real-world case studies, including examples involving GCase and lipid biomarkers, the speakers will illustrate how a coherent chain of evidence can reduce uncertainty and strengthen confidence in development decisions.

Speakers

The webinar features experts from CHDR and Ardena, including:

• Philip Kremer, Research Director Neurology, CHDR

• Theo de Boer, Scientific Director, Ardena

• Nick Woudberg, Business Development Director, Ardena

• Arjen Kol, Lead Scientist, Ardena

Practical information

Date: 19 October 2026
Time: 11:00 AM ET
Format: Online webinar

Register for the webinar here.